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Host proteins are incorporated both on and inside human immunodeficiency virus type 1 (HIV-1) virions. To identify cellular
proteins inside HIV-1, virion preparations were treated by a protease-digestion technique that removes external host proteins,
allowing for the study of the proteins inside the virus. Treated HIV-1 preparations were analyzed by immunoblot, high-
pressure liquid chromatography, and protein sequence analyses. These analyses identified several cellular proteins inside
HIV-1: elongation factor 1a, glyceraldehyde-3-phosphate dehydrogenase, HS-1, phosphatidylethanolamine-binding protein,
Pin1, Lck, Nm23-H1, and the C-terminal tail of CD43. Several of these proteins were found as fragments of their full-sized
proteins that appear to be generated by our protease treatment of the virions, the HIV-1 protease, or a cellular protease.
Recent advances in cell biology and biochemistry have identified some of these proteins as actin-binding proteins. These
results support the hypothesis that actin filaments are incorporated into the virion and may provide additional clues for the
understanding of the interaction between viral and cellular proteins during assembly and budding. © 2000 Academic Press
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HINTRODUCTION
Cellular proteins are incorporated into human immu-
nodeficiency virus type 1 (HIV-1) virions during assembly
(reviewed in Ott, 1997). Because retroviruses bud
through the plasma membrane, some of these proteins
may be incorporated due to their presence at the site of
viral budding. Although this process would be expected
to be random, it has been noted that cell surface proteins
appear to be excluded from enveloped virions (Zavada,
1982). Recently, it has been shown that CD4/Lck com-
plexes are excluded from HIV-1 (Henriksson and Bosch,
1998). These observations indicate that viruses actively
exclude some proteins from the virion or that virions bud
from specific regions of the plasma membrane that do
not contain these proteins. Because host proteins are
likely to be involved in the transport, assembly, and
budding of retroviruses, these proteins might also be
incorporated as a result of their interactions with the
structural proteins of the assembling virus. Finally, a
cellular protein might also be incorporated to provide a
function for the mature virus, either extracellularly or
during early infection events (i.e., uncoating and reverse
transcription).
The study of proteins inside retroviruses is compli-
cated by potential contamination of the viral preparation
with cellular proteins, either within microvesicles (Bess1 To whom reprint requests should be addressed. Fax: (301) 846-
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4et al., 1997; Gluschankof et al., 1997) or nonspecifically
adhered to the viral exterior. Previously, we developed a
method that uses protease digestion and sucrose den-
sity centrifugation to remove these sources of contami-
nation from virion preparations (Ott et al., 1995a). With
this method, more than 95% of the microvesicle-associ-
ated protein is removed from virion preparations (Ott et
al., 1996). This technique was used to produce prepara-
tions of treated HIV-1MN virions so that the internal pro-
eins could be analyzed by immunoblot, high-pressure
iquid chromatography (HPLC), and protein sequence
nalysis. Our results identified several cellular proteins
nside the HIV-1 virion in addition to those already char-
cterized. Some of these are actin filament-binding and
ctin-associated proteins, a finding that suggests the
ncorporation of the actin cytoskeleton into the virion
uring budding.
RESULTS AND DISCUSSION
ubtilisin treatment of HIV-1MN
A virus preparation produced from the Clone 4-13 cell
line (Ott et al., 1995b), a single cell clone isolated from
IV-1MN-infected H9 cells, was digested with subtilisin,
and the digested virions were isolated by sucrose den-
sity centrifugation. Amino acid analysis of the total pro-
tein present before and after treatment showed that only
75% of the initial amount of protein was present in the
treated sample. It is likely that this 25% loss is due to the
removal of proteins outside the virus: surface proteins,
2
m
n
5
a
t
d
c
v
P
t
m
43CELLULAR PROTEINS INSIDE HIV-1microvesicles, and cellular proteins that may simply ad-
here to the virion. It should be noted that preparations
produced from Clone 4 and its subcloned cell lines such
as Clone 4-13 (Ott et al., 1995b) have been shown to
produce preparations that have remarkably few mi-
crovesicles compared with virus stocks that are pro-
duced from acutely infected H9 cells (Bess et al., 1997).
Additionally, these stocks were rigorously purified by
density centrifugation (Bess et al., 1992). Therefore, viral
preparations grown in other cells or produced by other
methods may lose more of their protein content after
treatment with this technique.
Cellular proteins inside HIV-1
The results of our HPLC, protein sequence, Coomas-
sie blue-stained SDS–PAGE (C–PAGE), and immunoblot
analyses are summarized in Table 1. Where feasible, the
amount of an internal host protein was determined by a
comparison of the relative A206 peak area for the cellular
protein versus that of p17MA in the HPLC chromatogram.
The results, normalized for molecular weight differences,
are presented in Table 1 as a percentage of the Gag
molecules found in the HPLC. The findings for each
protein are presented and discussed below.
Elongation factor-1a
Previous protein sequence analyses of HPLC-fraction-
TABLE 1
Proteins Detected in HIV-1
Protein Page/immunoblota Sequenceb Amountc Microvesiclesd
EF1a 53kDa NDe ND 1
36kDa ND 2
30kDa aa 239 f 6% (150) ND
25kDa ND 2
16kDa 338 f, 341 f ND
GAPDH 37kDa aa 2 f 1% (25) 1
Nm23-H1 23kDa ND ND 1
PBP 23kDa aa 1g 1% (25) ND
HS-1 15kDa aa 13 f 1% (25) ND
Lck 56kDa ND ND 1
CD-43 21kDa aa 277 f 1% (25) ND
Pin 1 16kDa ND ND 1
a Size determined by C-PAGE or immunoblotting.
b N-terminus of peptide as determined by protein sequence.
c Estimated amount of protein as a percentage of Gag molecules
(average number of molecules per virion assuming 2500 Gag/virion;
Bess et al., 1992; Layne et al., 1992; Piatak et al., 1993; Summers et al.,
1993).
d Presence of protein in microvesicles (1 5 present, 2 5 not
detected, and ND 5 not determined).
e ND, not determined.
f Amino acid position from the deduced protein sequence.
g Amino acid position from the actual (mature) protein sequence.ated HIV-1 preparations have detected fragments of
elongation factor-1a (EF1a) (L. E. Henderson, D. G. John-
rson, and R. C. Sowder II, unpublished data). To deter-
mine whether EF1a is present in the virion, digested and
ock-digested HIV-1MN virions were analyzed by immu-
oblot analysis. The results showed that little, if any,
3-kDa full-length EF1a was detected (Fig. 1A). In immu-
noblots of other preparations, larger amounts of the
full-length protein were detected in the mock-treated
samples and were mostly removed by protease treat-
ment (data not shown). The low level of the full-length
band in the immunoblots, as well as loss of this band in
other experiments, indicates that most of the full-length
FIG. 1. Analysis of EF1a. (A) EF1a immunoblot of virion, microvesicle,
nd cell lysate samples are identified above the respective lanes. The
otal amount of protein loaded in each lane is 80 mg for HIV-1 (before
igestion), 20 mg for the H9 microvesicles, and 10 mg for the endothelial
ell lysate. The lanes containing mock-digested and subtilisin-digested
irions are indicated by 2 and 1, respectively. The digested NL4-3 and
RD25G samples represent approximately 600,000 cpm of reverse
ranscriptase activity. Molecular weights, as determined by relative
obility, are indicated at the left. (B) An HPLC chromatogram of theegion that contains EF1a is presented with immunoblots of selected
fractions shown under their respective areas.
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44 OTT ET AL.EF1a is not inside the virion. Immunoblot analysis of
icrovesicle preparations produced from H9 cells
learly showed a strong band corresponding to full-
ength EF1a (Fig. 1A). Therefore, most of the full-length
EF1a detected in virion preparations is likely to be as-
sociated with copurifying microvesicles.
The majority of the EF1a signal in the virus samples
as present as a 36-kDa band that was not sensitive to
rotease treatment (Fig. 1A and data not shown). Addi-
ionally, a faintly reacting band at 25 kDa was detected in
he immunoblot (Fig. 1A). Microvesicle samples con-
ained only full-length EF1a and none of the fragments,
suggesting that these fragments are specific to virions.
However, an uninfected endothelial cell lysate did con-
tain both the full-length and 36-kDa species (Fig. 1A). The
identity of this 36-kDa species is not clear, although
other cell lysates, including those from H9 cells, contain
this reacting band (data not shown). Possibly, it is a
proteolytic fragment generated by a cellular protease.
Immunoblot analysis of HPLC fractions in the region
that has been previously shown to contain EF1a re-
vealed two different species of EF1a: one at 25 kDa (in
ractions 158 and 159) and another at 36 kDa (fraction
63 trailing to 166) (Fig. 1B). However, attempts at se-
uencing these bands were not successful, suggesting
hat the N-termini of these proteins might be blocked. It
as been previously shown that the N-terminus of EF1a
is blocked to Edman degradation sequencing (Dever et
al., 1989; Gonen et al., 1994; Yang et al., 1990). Therefore,
based on the immunoblot data and their resistance to
sequencing, these bands appear to be the N-terminal
portions of EF1a fragments.
In addition to these bands, protein sequence analysis
of a 30-kDa protein found in HPLC fractions 163–164
produced the sequence of LEALDXILP (X denotes an
amino acid that was not resolved by the analysis), which
corresponds to amino acid 239 of EF1a (Fig. 2 and Table
). Additional sequence analysis found smaller EF1a,
16-kDa C-terminal fragments: AGFTAQVIILNHPGQIS at
amino acid (aa) 338 and TAQVIILNHPGQISAGYAPV at aa
341 in fractions 158 and 156, respectively (Fig. 2 and
Table 1). Based on the apparent molecular weights of
these latter fragments and the known EF1a sequence,
the 16-kDa fragments appear to consist of the complete,
or nearly intact, C-terminus of EF1a. The 30-kDa frag-
ment has a somewhat larger size than expected for an
EF1a sequence starting at aa 239 (expected size, 26
Da). EF1a immunoblots failed to detect these frag-
ents, suggesting that the epitope of the monoclonal
ntibody is not present within these EF1a C-terminal
fragments.
In light of these combined immunoblot and sequence
data, it appears that we have found both ends of three
EF1a cleavage products: a 25-kDa N-terminal fragment
identified by immunoblot) with a 30-kDa C-terminal frag-
ent (starting at aa 239 as identified by sequence anal-sis) and a 36-kDa N-terminal fragment (identified by
mmunoblot) with two 16-kDa C-terminal fragments
starting at aas. 338 and 341 as identified by sequence
nalysis). Based on the HPLC, C–PAGE, and sequence
nalyses for these three C-terminal fragments, the
mount of EF1a molecules present in the virion is at
approximately 6% of the level of Gag. We have been
unable to find the fraction that contains full-length EF1a,
o this estimate does not include this species.
Previous studies have found that HIV-1 protease can
leave actin and other cellular proteins (reviewed in
oorman et al., 1991) and that actin fragments, presum-
bly cleaved by protease, have been found inside HIV-1
irions (Ott et al., 1996). The sequences surrounding the
39 site (GTTL/LEAL) of the 30-kDa fragment would be
xpected to be cleaved by HIV-1 protease based on the
oorman algorithm (h 5 0.38 with h 5 0.13 as a predic-
ive cutoff) (Poorman et al., 1991). In contrast, the sites in
he 16-kDa proteins, at aa 338 (MEAA/GFTA; h 5 4 3
024) and 341 (AAGF/TAQV; h 5 3 3 1024), are not
redicted to be substrates for HIV-1 protease. Thus it is
ot clear how these two fragments are produced; per-
aps they are generated by a cellular protease as we
ave proposed above.
To test the effect of HIV-1 protease activity on EF1a
incorporation, virions of a protease-deficient mutant
were examined. This virus, PRD25G, contains a site-
25
FIG. 2. HPLC and sequence analysis of HIV-1MN. The fractions con-
taining the cellular proteins that were identified by protein sequencing
are indicated by shading (shaded peaks may contain more than one
protein) and by fraction number below the chromatogram. The HPLC
fractions containing Gag proteins are labeled above the respective
peaks.directed mutation in the active site of protease (Asp to
Gly) that inactivates the enzyme in the pNL4-3 molecular
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45CELLULAR PROTEINS INSIDE HIV-1clone. Both parental and mutant virions produced from
transfection were subjected to the subtilisin-sucrose
centrifugation treatment (to remove contaminating pro-
teins) and then examined by EF1a immunoblot (Fig. 1A).
The lane containing wild-type NL4-3 virions had a prom-
inent band at 36 kDa with only a light band at 53 kDa. In
contrast, the PRD25G sample contained nearly all of the
EF1a as the 53-kDa full-length, or near-full-length protein
with little of the 36-kDa species present. The 25-kDa
species is present in the wild-type blot as a faint band
due to the relatively small amount of virions produced by
transfection. This band is not present in the treated
protease lane, consistent with the prediction presented
above. The increased level of full-length EF1a supports
the hypothesis that EF1a is cleaved by the HIV-1 pro-
ease. The absence of the 36-kDa protein in the protease
utant (and in microvesicles) may indicate that there is
ossibly some requirement for protease activity either for
he generation or the incorporation of this species. Better
haracterization of the 36-kDa protein in virions and in
ells should make this protease dependence more clear.
The reason for EF1a incorporation into the virion is not
nown. Because this protein is an essential part of the
ranslation machinery, practical inhibitors and mutant
ell lines to test its function for HIV-1 are not available.
ecently, EF1a has been shown to be an actin bundling
protein (Edmonds et al., 1995; Lui et al., 1998), and this
interaction has been proposed as a link between the
cytoskeleton and translation. This association may be
responsible for localization of some proteins by regulat-
ing and spatially restricting their translation via the at-
tachment of mRNAs along regions of the actin network
(Bassell and Singer, 1997). Actin has been found in HIV-1
virions (Ott et al., 1996); therefore it is possible that some
of the actin and EF1a are incorporated as these special-
ized actin-EF1a filaments. Inside the cell, these square-
haped filaments are made up of a 2:1 ratio of actin to
F1a. Interestingly, we have found that actin and EF1a
are present inside the virion at a similar 2:1 ratio (actin at
10–15% [Ott et al., 1996] and EF1a at 6%, respectively),
which is consistent with these structures being incorpo-
rated. Furthermore, both proteolytic fragments of actin
(Ott et al., 1996) and EF1a, apparently cleaved by HIV-1
rotease, are found inside the virion. This might be due
o the action of the HIV-1 protease on a filament complex.
dditional experiments that study the assembling virus
nside the cell as well as a characterization of the actin
omplexes found in the virion would help to address the
otential involvement of these specialized actin-EF1a
structures in the virus life cycle.
Glyceraldehyde-3-phosphate dehydrogenase
Our sequence analysis of a 37-kDa protein in HPLC
fraction 208 of the treated virions yielded the N-termi-
nal sequence of glyceraldehyde-3-phosphate dehydro-genase (GAPDH), GKVKVGVNGF (Table 1 and Fig. 2).
Immunoblot analysis of mock and protease-treated
virions detected a small amount of GAPDH in both
samples (Fig. 3). Although the intensity of the band in
the digested sample was lower than that in the mock-
treated sample, this band was still readily detected.
This shows that a significant amount of the GAPDH in
the preparation was resistant to subtilisin treatment
FIG. 3. Analysis of digested HIV-1MN virions. Immunoblots for cellular
proteins are presented with the antiserum used for each protein indi-
cated above each blot. The amounts applied to the blots are as follows:
HIV-1 (20 mg/lane before treatment, except for GAPDH, which is 40
mg/lane), H9 microvesicles (20 mg/lane), and cell lysate (10 mg of HeLa
or endothelial cell lysates). The samples are identified above the
respective lanes. The lanes containing mock-digested virions are indi-
cated by 2, whereas the lanes containing subtilisin-digested virions
are indicated with 1. Molecular weights, as determined by relative
mobility, are indicated at the left.and thus inside the virion. Based on the HPLC,
C–PAGE, and protein sequencing data, the amount of
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46 OTT ET AL.GAPDH inside virions is approximately 1% of the level
of Gag.
GAPDH is known to be or has been implicated to be
involved in many different cellular processes: glycolysis,
tRNA export, mRNA translation, DNA repair, and endo-
cytosis (reviewed in Sirover, 1997). As with EF1a, GAPDH
has no feasible inhibitors or mutants for testing the
significance of its incorporation on the HIV-1 life cycle.
GAPDH has also been found to bind actin filaments in
vitro (Mejean et al., 1989) and therefore could be incor-
porated with actin. However, this protein has several
other roles in the cell. It is an AU-rich RNA-binding
protein (Nagy and Rigby, 1995) and has been found to
bind to several viral RNAs, including a recently reported
interaction with the hepatitis virus RNA post-transcrip-
tional regulatory element (Zang et al., 1998). In one re-
ort, GAPDH has been shown to enhance gene expres-
ion by affecting translation (Sugahara et al., 1995).
APDH also possesses a uracil DNA glycosylase activ-
ty, an activity that has been proposed to reduce the
umber of mutations during the reverse transcription
rocess (Selig et al., 1997).
m23-H1
The presence of GAPDH in the virion led us to look for
m23-H1. Recently, heterodimers of GAPDH and Nm23-
1, a protein that has been originally characterized as a
ucleoside diphosphate kinase, have been found to pos-
ess a protein phosphotransferase activity (Engel et al.,
998). Immunoblot analysis of both digested and mock-
igested virions detected similar amounts of the 23-kDa
m23-H1 protein (Fig. 3), suggesting that this protein is
resent inside the virion. Attempts to locate this protein
n the HPLC fractions were not successful. The presence
f this protein in the virion opens the possibility that
APDH and Nm23-H1 could be multimerized and active
s a protein phosphotransferase.
hosphatitylethnolamine-binding protein
Protein sequence analysis of fraction 164 detected a
3-kDa protein that contained the N-terminal sequence
orresponding to the N-terminus of phosphatitylethno-
amine-binding protein (PBP), PVDLSKXXXP. The appar-
nt size of this protein suggests that the PBP inside the
ell is full or nearly full length. Based on the HPLC profile
nd C–PAGE data, PBP is present at approximately 1% of
he level of Gag molecules.
The cellular function of PBP has not been clearly
emonstrated; however, this protein is present at the
lasma membrane, possibly restricted to specific re-
ions and has been proposed to play a role in the
rganization and localization of lipids and possibly pro-eins in the plasma membrane (Frayne et al., 1998). The
resence of this protein inside the virion may provide a
alue as to whether HIV-1 buds from a particular region of
he plasma membrane.
S-1
Protein sequence analysis of a 15-kDa band in fraction
39 produced the sequence of HS-1, starting with amino
cid 14 from the deduced amino acid sequence (Kita-
ura et al., 1989) (Table 1 and Fig. 2). Because full-length
S1 has a molecular weight of 73 kDa, the protein that
e have isolated is a fragment of HS-1. Based on the
PLC data, approximately 1% of this fragment is present
nside the virion compared with the amount of Gag mol-
cules in the virion. Immunoblot analysis with an HS-1
onoclonal antibody did not detect this protein in the
irion. This may be due to the absence of the antibody’s
pitope in this fragment, the small amount of protein
resent, or the sensitivity of the antibody.
HS-1 is a protein that associates with Lck, is phos-
horylated by Lck on T cell receptor activation, and
ppears to be important in T cell signal transduction
Takemoto et al., 1996). This protein binds actin filaments,
ossibly coordinating signal transduction with actin ar-
hitecture, and its actin-binding motifs are biologically
mportant for HS1 function (He et al., 1998). HS-1 con-
ains three motifs in its N-terminus that bind both actin
nd phosphatidylinositol-4,5,-bisphosphate (a Ras sec-
nd messenger that induces actin polymerization) (Take-
oto et al., 1995). Based on our sequence data and its
5-kDa apparent size, this HS-1 fragment should contain
t least one and possibly two of the actin-binding re-
eats. Therefore, it is possible that this protein is incor-
orated with actin.
ck
The presence of HS-1 inside virions led us to ask if Lck
as also present in HIV-1. Immunoblot analysis of virions
hat were treated with and without subtilisin showed that
irions did contain Lck and that it is present inside the
irus (Fig. 3). A series of immunoblotting experiments
ocalized Lck to the propanol fractions 360–410 of HPLC
data not shown). Unfortunately, proteins found in this
egion of the HPLC elute over a large number of frac-
ions; therefore, it is very difficult to determine how much
ck is present in virions based on this HPLC analysis.
D-43
Protein sequence analysis of a 21-kDa band that was
n fraction 139 produced the sequence of CD-43 starting
ith amino acid 277 of the precursor (256 of the mature
rotein) (Pallant et al., 1989) LLXRRRQKRRTG. This frag-
ent corresponds to the cytoplasmic tail of this surface
rotein. Because this preparation was digested with sub-
ilisin, the extracellular domain is expected to be missing
TMs is the case for the gp41 protein (Ott et al., 1995a).
Therefore, the CD-43 fragment found inside the virions is
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47CELLULAR PROTEINS INSIDE HIV-1likely to be the result of subtilisin treatment. However,
subtilisin digestion should theoretically digest CD-43
down to the N-terminal end of the proposed membrane
spanning region (aa 236; Pallant et al., 1989). Our se-
quence, starting at aa 256, is nearer to the putative
C-terminal end (aa 258). The experimental determination
of CD-43 structure might help explain this result. An
alternative explanation, that this fragment was created
by HIV-1 protease, does not seem probable because the
site that would have been cleaved, VALL/LLWR, is not
predicted to be a substrate for protease by the Poorman
algorithm (h 5 1 3 1023). Based on the amount of this
ytoplasmic tail inside the virion, CD-43 is present at
pproximately 1% the number of p17MA molecules or 10%
f the amount of Env that is thought to be on the virion
urface (Gelderblom, 1991). This result confirms the re-
ults of other groups who have found CD-43 on the
urface of cells (Frank et al., 1996; Gluschankof et al.,
1997; Orentas and Hildreth, 1993).
Pin1
Two prolyl isomerases (immunophilins), cyclophilin A
and FK506-binding protein 12, have been shown to be
incorporated into HIV-1 (Briggs et al., 1999; Franke et al.,
1994; Ott et al., 1995a; Thali et al., 1994), and cyclophilin
A has been shown to be required for efficient initiation of
reverse transcription (Braaten et al., 1996). Recently, the
Pin1 protein has been isolated and characterized as a
novel prolyl isomerase that is distinct from the cyclophi-
lin and FK506-binding protein families (Lu et al., 1996).
Unlike other prolyl isomerases, this enzyme specifically
isomerizes the bond between either phosphoserine or
phosphothreonine and proline (Yaffe et al., 1997). Fur-
thermore, Pin1 binds and regulates the function of a
defined subset of phosphoproteins (Shen et al., 1998).
Interestingly, microsequencing of proteins purified using
Pin1 affinity chromatography revealed a peptide se-
quence, SYELPDGQVIT, which corresponded to actin be-
ginning at aa 241 of the unprocessed sequence (Shen
and K. P. Lu, unpublished data). This result suggests that
Pin1 can also bind actin. Because virions contain several
actin-binding proteins and Pr55Gag contains several S-P
airs that could be substrates for this enzyme, we exam-
ned HIV-1 virions for the presence of Pin1. Digested
irions were examined by immunoblot analysis with an-
iserum to Pin1. The results showed that Pin1 was
resent in both the subtilisin-treated and mock-treated
amples; thus Pin1 appears to be inside the virions (Fig.
). Attempts at sequencing Pin1 from HPLC fractions
ailed to produce Pin1 sequence, preventing an estimate
f the amount of protein in the virion.
The finding of Pin1 in the virion suggests that this
pecific prolyl isomerase might act on phosphoproteins
n the virion. The identification and development of new
w
mnhibitors of Pin1 might allow for future studies on a
ossible function of Pin1 in HIV-1 replication.
sp60 is removed by subtilisin treatment
One of the cellular proteins that we have looked for in
irion preparations is the protein chaperone Hsp60. Im-
unoblotting of virion preparations demonstrated that
lthough Hsp60 was detectable in the mock-treated
reparation, protease treatment eliminated nearly all of
his signal (Fig. 3). An analysis of microvesicles from H9
ells also did not detect any Hsp60. Therefore, the ma-
ority of the Hsp60 found in viral preparations appears to
e outside of the virus, possibly adhered onto the virion
urface, and not inside the virions or associated with
icrovesicles. Because proteins other than those asso-
iated with microvesicles contaminate HIV-1 prepara-
ions, physical removal of the microvesicles themselves
ay not be sufficient to study the proteins inside the
irion. These data also identify Hsp60 as a marker for
ellular protein contamination in virus preparations pro-
uced from H9 cells.
rotease treatment of microvesicles
Previously, we have shown through electron micros-
opy and protein analysis that microvesicles and the
roteins associated with them are removed by our pro-
ease digestion and centrifugation method (Ott et al.,
995a; Ott et al., 1996). To demonstrate the amount of
icrovesicle-associated protein removed by this proce-
ure, microvesicles were treated with the same method
s the HIV-1 virions. The proteins remaining in the
reated sample versus those in the starting material were
nalyzed by C–PAGE analysis. The results, shown in Fig.
, revealed that although the original microvesicle sam-
le had many bands corresponding to a variety of cellu-
ar proteins, the treated sample contained no discreet
ands. Some staining was present low in the gel, which
s usually characteristic of the presence of lipids but
ould also be protein fragments that remained after treat-
ent. These results show that the majority of proteins
ound in microvesicles are removed by the subtilisin
reatment. Immunoblot analysis of treated and untreated
icrovesicles using reagents that detect GAPDH, NM23-
1, Lck, Pin1, and EF1a showed that most of these
roteins were also removed by the technique (Fig. 4B). A
omparison of the treated microvesicles with a dilution
eries of untreated material showed that this technique
emoved 95% or more of the microvesicle-associated
rotein, which is consistent with our previous results
ith actin (Ott et al., 1996). The data presented above
emonstrate that our treatment essentially removes the
icrovesicle-associated protein from virion prepara-
ions. When comparing immunoblots of microvesicles
ith those of virion preparations, it should be noted that
icrovesicles constitute approximately 10% of the parti-
b
m
lanes.
ibody u
48 OTT ET AL.cles in Clone 4 preparations (Bess et al., 1997; Ott et al.,
1995a). Therefore, there are considerably more mi-
crovesicle-associated proteins in a microvesicle prepa-
ration than contaminate a Clone 4 virion preparation.
Taken together, these results and those from the di-
gested virions indicate that the proteins identified above
are present inside the virion.
Host proteins in virions
This study has identified several actin-binding and
plasma membrane-associated proteins that are present
in protease-treated virions. However, other proteins iso-
lated by HPLC did not yield protein sequences, probably
due to the common modifications (e.g., N-acetylation)
that block the N-termini of cellular proteins. The amounts
of these blocked proteins in HIV-1 preparations currently
do not allow for internal sequencing; the list presented
here is not complete because important proteins that are
incorporated into the virion may not have been identified.
Further studies with more sensitive techniques would
certainly uncover more proteins inside the virion.
Some of the proteins isolated and identified in this
study (e.g., EF1a and GAPDH) were originally described
as having other essential roles in cellular biology. Based
on these roles, they would not be expected to be incor-
porated into virions. However, both of these proteins also
appear to bind actin and possibly provide other functions
in the cell. It is becoming clearer that abundant and
rather well characterized proteins can have multiple di-
verse and unrelated roles inside the cell (Jeffery, 1999).
Given the structural nature of most of the cellular
FIG. 4. Treatment of microvesicles. (A) C–PAGE analysis of 30-mg
presented. (B) Semiquantitative immunoblots of treated and untreate
treatment, 1 and 2, respectively, indicated above the corresponding
microvesicles (labeled (in mg) above each lane). The antiserum or antproteins described here, they could be incorporated ei-
ther nonspecifically at the site of budding or by virtue ofan interaction between cytoskeleton and viral proteins.
However, an active role in infection cannot be ruled out.
When considering the role of any host protein in the
virion, it is important to note that only a tiny fraction,
estimated at between 1023 and 1027, of the viral particles
are infectious (Layne et al., 1992; Piatak et al., 1993).
Protein analyses of virions can detect only the molecules
present within the whole population of virions, not their
distribution among the virions. It is quite possible that a
few infectious virions could contain a particular cellular
protein that is absent in the vastly larger number of
defective virions.
It has been proposed that enveloped viruses generally
interact with, and possibly use, the actin cytoskeleton
during assembly and budding (Damsky et al., 1977; Wang
et al., 1976). Our previous studies have found a variety of
cellular proteins inside HIV-1. Many of these are clearly
members of the cytoskeleton (e.g., actin, ezrin, moesin,
and cofilin; Ott et al., 1996), supporting this hypothesis for
HIV-1. Additionally, the Pr55Gag precursor and p7NC have
een shown to be associated with actin and actin fila-
ents (Liu et al., 1999; Rey et al., 1996; Wilk et al., 1999).
Furthermore, inhibitors of the actin polymerization and
myosin kinase have been shown to inhibit HIV-1 budding
(Sasaki et al., 1995). Our finding that actin-binding and
actin-associated proteins are present inside HIV-1 is
consistent with these previous reports of actin/virus in-
teractions.
Although many studies circumstantially support the
proposal that retroviral proteins interact with actin fila-
ments (Edbauer and Naso, 1984; Liu et al., 1999; Luftig
es from untreated (2) and treated (1) microvesicle preparations is
ovesicles are presented with the amount of sample (in mg) and its
Lanes to the right of the treated lane contain dilutions of untreated
sed is identified above each blot.sampl
d micrand Lupo, 1994; Ott et al., 1996; Pearce-Pratt et al., 1994;
Rey et al., 1996; Sasaki et al., 1995; Wilk et al., 1999), one
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49CELLULAR PROTEINS INSIDE HIV-1study using fluorescent techniques has failed to find
convincing actin/Gag interactions (Perrin-Tricaud et al.,
1999). Therefore, the role of actin in the HIV-1 life cycle is
still unclear.
Our findings may provide important clues to the nature
of HIV-1 assembly and budding: some for its the mech-
anism and some for its location. Future advances in the
study of the cytoskeleton and cell structure should pro-
vide a clearer picture of the cell and possible interac-
tions with HIV-1 assembly. The results presented here
are being used as a starting point to conduct further
studies of the intracellular virion assembly process.
MATERIALS AND METHODS
Viral preparations
Virus was prepared from a single cell cloned, HIV-1MN-
infected H9 human T cell line, Clone 4-13 (Ott et al.,
1995b) by two rounds of sucrose density centrifugation
as previously described (Bess et al., 1992). Microvesicles
were produced by a similar procedure (Bess et al., 1997).
HIV-1NL4-3 and a protease mutant, PRD25G, were pro-
duced by calcium phosphate transfection into 293T cells
using a kit (5 Prime-3 Prime, Boulder, CO) as previously
described (Ott et al., 1999). For protease treatment, virion
reparations were digested in a solution of 1 mg/ml
ubtilisin (Boehringer-Mannheim Biochemicals, India-
apolis, IN) in 10 mM Tris–Cl, pH 8.0, and 1 mM EDTA for
8 h at 37°C. The reaction was stopped with 5 mg/ml
PMSF (final concentration), and the treated virions were
recovered by centrifugation through a 20% sucrose pad
in PBS (Life Technologies, Gaithersburg, MD). For milli-
gram quantities of virions (HIV-1MN), the preparations
ere centrifuged at 25,000 rpm for 1 h in an SW28Ti rotor
Beckman Instruments, Inc., Fullerton, CA), whereas mi-
rogram quantities (HIV-1NL4-3) were centrifuged at 55,000
rpm for 1 h in an SW60Ti rotor (Beckman Instruments,
Inc.).
Construction of protease mutant
HIV-1 containing a protease active site mutation,
PRD25G (nucleotide 2326 A to C), was produced using
PCR overlap mutagenesis as previously described (Ott et
al., 1999). An ApaI–BclI fragment carrying the mutation
was produced and then inserted back into the parental
pNL4-3 molecular clone (Adachi et al., 1987). The region
subjected to PCR amplification in the final clone was
sequenced to confirm the presence of the mutant and
the absence of unexpected mutations in the region that
could be produced during mutagenesis.
Protein analysis
For HPLC and protein sequence analysis, a virion
preparation of 120 mg total protein, as determined by the
Lowry method (Lowry et al., 1951), was treated as de-
Dscribed above. The material was assayed for protein
content by automated amino acid analysis and applied to
a reverse phase HPLC column using conditions as pre-
viously described (Henderson et al., 1992). Samples from
the fractions containing protein peaks were analyzed by
SDS–PAGE and C–PAGE. Fractions containing proteins
of interest were subjected PAGE analysis and blotted
onto PVDF membranes, followed by Ponseau S staining.
Immobilized bands of interest were excised and sub-
jected to protein sequence analysis as previously de-
scribed (Henderson et al., 1992). Immunoblotting analy-
sis of protease and mock-digested virions was carried
out as previously described (Henderson et al., 1988)
using enhanced chemiluminescence detection (Amer-
sham-Pharmacia Biotech, Inc., Piscataway, NJ). Mono-
clonal antibody to EF1a was obtained from Upstate Bio-
echnology, Inc. (Lake Placid, NY). Endothelial and HeLa
ell lysate controls were obtained from Transduction
aboratories, Inc. (Lexington, KY). Protein sequencing
as accomplished as previously described on either an
pplied Biosystems model 477 or a Procise model 494
icrosequencer (Foster City, CA).
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